Canbex Therapeutics

Canbex Therapeutics is dedicated to the development of novel compounds for the treatment of spasticity in multiple sclerosis (MS) and potentially other disorders. The goal of the Canbex program is to set a new standard in the treatment of spasticity, through improved tolerability. Canbex Therapeutics is based in London, UK.